Blume Capital Management Inc. Cuts Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Blume Capital Management Inc. lowered its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,509 shares of the financial services provider’s stock after selling 190 shares during the quarter. iShares Biotechnology ETF accounts for 1.5% of Blume Capital Management Inc.’s investment portfolio, making the stock its 27th largest holding. Blume Capital Management Inc. owned 0.11% of iShares Biotechnology ETF worth $6,810,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. HBK Sorce Advisory LLC grew its stake in shares of iShares Biotechnology ETF by 5.3% during the 4th quarter. HBK Sorce Advisory LLC now owns 2,196 shares of the financial services provider’s stock worth $290,000 after purchasing an additional 110 shares during the period. Avantax Advisory Services Inc. grew its stake in shares of iShares Biotechnology ETF by 21.5% during the 4th quarter. Avantax Advisory Services Inc. now owns 6,023 shares of the financial services provider’s stock worth $796,000 after purchasing an additional 1,064 shares during the period. Farther Finance Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 11.5% during the 4th quarter. Farther Finance Advisors LLC now owns 6,433 shares of the financial services provider’s stock worth $850,000 after purchasing an additional 663 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 22.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 3,205 shares of the financial services provider’s stock worth $424,000 after purchasing an additional 597 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 5.1% during the 4th quarter. HighTower Advisors LLC now owns 83,944 shares of the financial services provider’s stock worth $11,098,000 after purchasing an additional 4,047 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.8 %

NASDAQ:IBB opened at $133.14 on Friday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The stock has a market cap of $6.29 billion, a PE ratio of 24.52 and a beta of 0.84. The firm’s fifty day simple moving average is $136.24 and its 200-day simple moving average is $140.01.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.